MedTrace Logo

Safety & Efficacy of Nuberol Forte® in Pain Management

NCT04765787 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 399

Last updated 2021-11-10

No results posted yet for this study

Summary

The global prevalence of Musculoskeletal disorders (MSD) ranges from 14% to as high as 42%. In addition WHO also estimates that 40% of people over the age of 60 years suffer from MSD and about 80% of the people have had low back pain at some point in their life. In Pakistan, to estimate the prevalence of MSD, there is no data available based on the local population. Locally, studies were conducted on the specific subject pools mainly considering the work related musculoskeletal disorders and backache. However, no real data is available for the symptomatic management of painful musculoskeletal disorders in multiple settings to calculate more generalizable results. So this study is planned and if we found good results then it will help physicians to prescribe the above said medicine to all such cases.

Conditions

  • Musculoskeletal Disorder
  • Pain Management

Interventions

DRUG

Combination of Paracetamol 650mg + Orphenadrine 50mg

In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion

Sponsors & Collaborators

  • The Searle Company Limited Pakistan

    lead INDUSTRY

Principal Investigators

  • Asif Mahmood, Dr. · The Searle Company Limited

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-04-01
Completion
2021-08-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04765787 on ClinicalTrials.gov